Nuwellis Appoints Mike McCormick as Chief Executive Officer
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) appointed Mike McCormick as Chief Executive Officer, effective June 30, 2026. Current President, CEO, and Chairman John Erb will step down from executive duties and remain Chairman of the Board.
McCormick has over 30 years of medical technology leadership and previously served as a Nuwellis Board member.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NUWE
On the day this news was published, NUWE declined 0.88%, reflecting a mild negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $15K from the company's valuation, bringing the market cap to $1.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Partnership expansion | Positive | +4.7% | Expanded collaboration to install and upgrade Aquadex SmartFlow devices in pediatrics. |
| Jun 08 | Offering closing | Negative | -1.0% | Closed $6.0M registered public offering with common and pre-funded warrants. |
| Jun 05 | Offering pricing | Negative | -61.2% | Priced $6M public offering with large Series C and D warrant coverage. |
| May 14 | Regulatory meeting | Positive | -1.0% | Successful FDA pre-submission 510(k) meeting on Aquadex pediatric label expansion. |
| May 12 | Earnings update | Negative | -1.0% | Q1 2026 results with higher revenue but sizable losses and limited cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with capital raises and operational progress often aligned with share moves: offerings coincided with declines, while partnership news saw a modest gain. One positive regulatory update drew a mild negative reaction.
Over the past months, Nuwellis reported Q1 2026 results with net sales of $2.4 million and higher gross margin but continuing losses and limited cash. The company advanced its Aquadex platform, including an FDA pre-submission 510(k) meeting to expand labeling to patients ≥5 kg. Capital needs prompted multiple offerings targeting roughly $6.0 million in gross proceeds, which weighed heavily on the stock. A recent collaboration to place new Aquadex SmartFlow devices produced a positive price reaction, contrasting with generally negative responses to financing and going-concern disclosures.
Regulatory & Risk Context
An effective S-3 shelf from 2026-02-03 registers up to 4,279,325 resale shares from existing warrants. Nuwellis would not receive proceeds from stockholder resales but could receive up to $28 million if all registered warrants are exercised for cash, indicating additional potential share issuance over time.
Key Terms
cardiorenal medical
precision fluid management medical
capital formation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board
MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the appointment of Mike McCormick as Chief Executive Officer, effective June 30, 2026. John Erb, who currently serves as President, CEO, and Chairman of the Board, will transition from his executive leadership role and continue serving as Chairman of the Board.
“Mike brings an exceptional combination of operational leadership, commercial expertise, and strategic vision,” said Erb. “His deep understanding of the medical device industry and proven track record of building and scaling innovative healthcare companies make him uniquely qualified to lead Nuwellis into its next phase of growth. I look forward to supporting Mike and the management team as Chairman of the Board.”
“Nuwellis has an important opportunity to expand the role of precision fluid management in cardiorenal care,” said McCormick. “I am excited to work with our employees, leadership team, Board, clinicians, and customers to build on the Company’s momentum, strengthen commercial execution, advance our pipeline, and create value for patients, healthcare providers, and shareholders.”
McCormick is a seasoned medical technology executive with more than three decades of leadership experience spanning product development, commercialization, corporate strategy, and value creation. He served as a Board Member and Independent Director of Nuwellis from June 2023 through January 2026. Throughout his career, McCormick has founded, scaled, and led both public and private medical technology companies, creating value through successful commercialization, operational execution, capital formation, and strategic transactions across multiple healthcare markets.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
